REDWOOD CITY, CA -- (Marketwired) -- 12/16/13 -- Versartis, Inc. today announced the expansion of its…
Continue ReadingTag: versartis
Versartis Closes $20 Million Series D Venture Financing
New Capital Will Support Preparations for Phase 3 Trial of Long-Acting Human Growth Hormone in Pediatric…
Continue ReadingVersartis Presents Latest Positive Results From Its Pediatric Study of Long-Acting Growth Hormone Treatment at International Endocrinology Conference
MILAN, ITALY -- (Marketwired) -- 09/22/13 -- Versartis, Inc. today released the latest positive results from…
Continue ReadingVersartis Receives Orphan Drug Status for Its Novel Long-Acting Growth Hormone Treatment From European Commission
VRS-317 Clinical Update to Be Presented at Upcoming Endocrinology Conference in Europe
Continue ReadingJournal of Clinical Endocrinology & Metabolism Publishes Positive Versartis Phase I Data
VRS-317 Is Versartis- Proprietary Long-Acting Growth Hormone Treatment
Continue ReadingVersartis Closes $25 Million Series C Financing
New Capital Will Fund Pediatric Clinical Development of Long-Acting Human Growth Hormone
Continue ReadingVersartis Phase 1 Clinical Results of Once Monthly Human Growth Hormone Presented to European Society for Paediatric Endocrinology
Positive Clinical Study of VRS-317 to Support Initiation of Efficacy Study
Continue ReadingPositive Results From Versartis Phase 1 Clinical Study of Once Monthly Human Growth Hormone Treatment Presented at ENDO 2012
Positive Data Support Initiation of Next Study of VRS-317
Continue ReadingVersartis Announces Publication of Preclinical Data for Once Monthly Human Growth Hormone Treatment in Journal of Pharmaceutical Sciences
Phase I Clinical Data to Be Presented Later This Month at ENDO 2012
Continue Reading